Alamar Biosciences Expands Immune Profiling with NULISAseq™ Immune 340 Panel
Event summary
- Alamar Biosciences launched the NULISAseq™ Immune 340 Panel on July 28, 2026.
- The panel measures approximately 340 immune-related proteins from a single sample.
- The panel is designed for translational research and drug development in cancer, cardiovascular, metabolic, autoimmune diseases, and aging.
- Sanofi's Translational Medicine Unit highlighted the panel's ability to detect previously undetectable immune mediators.
The big picture
Alamar Biosciences' launch of the NULISAseq™ Immune 340 Panel underscores the growing importance of high-sensitivity proteomics in early disease detection and drug development. The panel's ability to measure previously undetectable immune mediators positions it as a critical tool for biomarker discovery and patient stratification, addressing a significant gap in current research capabilities.
What we're watching
- Adoption Pace
- How quickly Sanofi and other pharmaceutical companies will integrate the NULISAseq™ Immune 340 Panel into their research pipelines.
- Market Differentiation
- Whether Alamar Biosciences can sustain its competitive edge in precision proteomics amid intense market competition.
- Regulatory Hurdles
- The potential for increased regulatory scrutiny as the panel is used in clinical and diagnostic applications.
Related topics